Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D03SIA
|
|||
| Former ID |
DIB002743
|
|||
| Drug Name |
OBI-1
|
|||
| Synonyms |
Porcine rFVIII, Ipsen/Inspiration; Porcine rFVIII, Octagen/Ipsen; Porcine rFactor VIII, Ipsen/Inspiration; Porcine rFactor VIII, Octagen/Ipsen; Recombinant porcine Factor VIII, Ipsen/Inspiration; Recombinant porcine Factor VIII, Octagen/Ipsen
Click to Show/Hide
|
|||
| Indication | Factor VIII deficiency [ICD-11: 3B10; ICD-10: D66] | Phase 3 | [1] | |
| Company |
Baxter international; inspiration biopharmaceuticals
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Coagulation factor VIII (F8) | Target Info | Modulator | [2] |
| KEGG Pathway | Complement and coagulation cascades | |||
| Panther Pathway | Blood coagulation | |||
| Pathwhiz Pathway | Coagulation | |||
| Reactome | Platelet degranulation | |||
| Intrinsic Pathway of Fibrin Clot Formation | ||||
| Common Pathway of Fibrin Clot Formation | ||||
| COPII (Coat Protein 2) Mediated Vesicle Transport | ||||
| Cargo concentration in the ER | ||||
| WikiPathways | Complement and Coagulation Cascades | |||
| Blood Clotting Cascade | ||||
| Formation of Fibrin Clot (Clotting Cascade) | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01434511) Study of Modified Recombinant Factor VIII (OBI-1) in Subjects With Congenital Hemophilia A. U.S. National Institutes of Health. | |||
| REF 2 | Efficacy and safety of OBI-1, an antihaemophilic factor VIII (recombinant), porcine sequence, in subjects with acquired haemophilia A. Haemophilia. 2015 Mar;21(2):162-70. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.